BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu J, Lubman DM, Kugathasan S, Denson LA, Hyams JS, Dubinsky MC, Griffiths AM, Baldassano RN, Noe JD, Rabizadeh S, Gulati AS, Rosh JR, Crandall WV, Higgins PDR, Stidham RW. Serum Protein Biomarkers of Fibrosis Aid in Risk Stratification of Future Stricturing Complications in Pediatric Crohn's Disease. Am J Gastroenterol 2019;114:777-85. [PMID: 31058681 DOI: 10.14309/ajg.0000000000000237] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Steiner CA, Berinstein JA, Louissaint J, Higgins PDR, Spence JR, Shannon C, Lu C, Stidham RW, Fletcher JG, Bruining DH, Feagan BG, Jairath V, Baker ME, Bettenworth D, Rieder F; Stenosis Therapy and Anti-Fibrotic Research (STAR) Consortium. Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00593-0. [PMID: 34089850 DOI: 10.1016/j.cgh.2021.05.054] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang J, Lin S, Brown JM, van Wagoner D, Fiocchi C, Rieder F. Novel mechanisms and clinical trial endpoints in intestinal fibrosis. Immunol Rev 2021;302:211-27. [PMID: 33993489 DOI: 10.1111/imr.12974] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC; Scientific Workshop Steering Committee . Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021;15:1431-42. [PMID: 33730756 DOI: 10.1093/ecco-jcc/jjab050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Ungaro RC, Hu L, Ji J, Nayar S, Kugathasan S, Denson LA, Hyams J, Dubinsky MC, Sands BE, Cho JH. Machine learning identifies novel blood protein predictors of penetrating and stricturing complications in newly diagnosed paediatric Crohn's disease. Aliment Pharmacol Ther 2021;53:281-90. [PMID: 33131065 DOI: 10.1111/apt.16136] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Halligan S, Boone D, Archer L, Ahmad T, Bloom S, Rodriguez-Justo M, Taylor SA, Mallett S. Prognostic biomarkers to identify patients likely to develop severe Crohn's disease: a systematic review. Health Technol Assess 2021;25:1-66. [PMID: 34225839 DOI: 10.3310/hta25450] [Reference Citation Analysis]
6 Porter AC, Aubrecht J, Birch C, Braun J, Cuff C, Dasgupta S, Gale JD, Hinton R, Hoffmann SC, Honig G, Linggi B, Schito M, Casteele NV, Sauer JM. Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions. Inflamm Bowel Dis 2020;26:1498-508. [PMID: 32840322 DOI: 10.1093/ibd/izaa215] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Minar P, Lehn C, Tsai YT, Jackson K, Rosen MJ, Denson LA. Elevated Pretreatment Plasma Oncostatin M Is Associated With Poor Biochemical Response to Infliximab. Crohns Colitis 360 2019;1:otz026. [PMID: 31667468 DOI: 10.1093/crocol/otz026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
8 Wang Y, Huang B, Jin T, Ocansey DKW, Jiang J, Mao F. Intestinal Fibrosis in Inflammatory Bowel Disease and the Prospects of Mesenchymal Stem Cell Therapy. Front Immunol 2022;13:835005. [DOI: 10.3389/fimmu.2022.835005] [Reference Citation Analysis]
9 Viladomiu M, Longman RS. Decoding the matrix: multiomics reveals host-microbe biomarker for inflammatory bowel disease. J Clin Invest 2021;131:148902. [PMID: 33938448 DOI: 10.1172/JCI148902] [Reference Citation Analysis]
10 Shihan MH, Kanwar M, Wang Y, Jackson EE, Faranda AP, Duncan MK. Fibronectin has multifunctional roles in posterior capsular opacification (PCO). Matrix Biol 2020;90:79-108. [PMID: 32173580 DOI: 10.1016/j.matbio.2020.02.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
11 He JS, Tan JY, Li XZ, Feng R, Xiong SS, Lin SN, Qiu Y, Mao R. Serum biomarkers of fibrostenotic Crohn's disease: Where are we now? J Dig Dis 2020;21:336-41. [PMID: 32496631 DOI: 10.1111/1751-2980.12913] [Reference Citation Analysis]
12 Jurickova I, Bonkowski E, Angerman E, Novak E, Huron A, Akers G, Iwasawa K, Braun T, Hadar R, Hooker M, Han S, Cutler DJ, Okou DT, Kugathasan S, Jegga A, Wells J, Takebe T, Mollen KP, Haberman Y, Denson LA. Eicosatetraynoic Acid and Butyrate Regulate Human Intestinal Organoid Mitochondrial and Extracellular Matrix Pathways Implicated in Crohn's Disease Strictures. Inflamm Bowel Dis 2022:izac037. [PMID: 35259271 DOI: 10.1093/ibd/izac037] [Reference Citation Analysis]